Literature DB >> 25608718

A scalable method to concentrate lentiviral vectors pseudotyped with measles virus glycoproteins.

M P Marino1, M Panigaj1, W Ou1, J Manirarora1, C-H Wei1, J Reiser1.   

Abstract

Lentiviral (LV) vectors have emerged as powerful tools for basic research and clinical applications because of their ability to stably transduce both dividing and nondividing cells. A wide range of viral envelope (Env) glycoproteins have the ability to associate with the membrane of LV vectors, a process that is referred to as pseudotyping. Pseudotyped vectors have the capacity to transduce specific cell types for specific applications. For example, LV vectors pseudotyped with the measles virus (MV)-derived hemagglutinin (H) and fusion (F) proteins have the ability to transduce quiescent lymphocytes. In addition, the MV H glycoprotein can be engineered allowing cell-specific targeting of LV vectors. One problem with MV glycoprotein-pseudotyped LV vectors is low titer during vector production. This results in the need to manufacture large volumes of the vectors and to concentrate them to appropriate titers. The commonly used centrifugation-based concentration techniques for LV vectors are not practical for large-scale vector manufacturing. Thus, there is a need for improved methods to concentrate LV vectors. In this study, we adapted an anion-exchange membrane chromatography method that we previously used in the context of LV vectors pseudotyped with the vesicular stomatitis virus glycoprotein to concentate MV glycoprotein-pseudotyped LV vectors. Up to 60% of the input vectors with an up to 5300-fold reduction in volume was achieved using this anion-exchange chromatography method in conjunction with a desalting/concentration step involving centrifugal filter units. This technique provides a rapid and scalable approach for concentrating MV-pseudotyped LV vectors that does not require an elaborate setup.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25608718     DOI: 10.1038/gt.2014.125

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  27 in total

1.  Developing novel lentiviral vectors into clinical products.

Authors:  Anna Leath; Kenneth Cornetta
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

Review 2.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

3.  Downstream processing of lentiviral vectors: releasing bottlenecks.

Authors:  Vanessa Bandeira; Cristina Peixoto; Ana F Rodrigues; Pedro E Cruz; Paula M Alves; Ana S Coroadinha; Manuel J T Carrondo
Journal:  Hum Gene Ther Methods       Date:  2012-08-30       Impact factor: 2.396

Review 4.  Measles virus: cellular receptors, tropism and pathogenesis.

Authors:  Yusuke Yanagi; Makoto Takeda; Shinji Ohno
Journal:  J Gen Virol       Date:  2006-10       Impact factor: 3.891

5.  T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing.

Authors:  Qi Zhou; Irene C Schneider; Inan Edes; Annemarie Honegger; Patricia Bach; Kurt Schönfeld; Axel Schambach; Winfried S Wels; Sabrina Kneissl; Wolfgang Uckert; Christian J Buchholz
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

6.  Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors.

Authors:  Brigitte Anliker; Tobias Abel; Sabrina Kneissl; Juraj Hlavaty; Antonio Caputi; Julia Brynza; Irene C Schneider; Robert C Münch; Helga Petznek; Roland E Kontermann; Ulrike Koehl; Ian C D Johnston; Kari Keinänen; Ulrike C Müller; Christine Hohenadl; Hannah Monyer; Klaus Cichutek; Christian J Buchholz
Journal:  Nat Methods       Date:  2010-10-10       Impact factor: 28.547

7.  A human lung carcinoma cell line supports efficient measles virus growth and syncytium formation via a SLAM- and CD46-independent mechanism.

Authors:  Makoto Takeda; Maino Tahara; Takao Hashiguchi; Takeshi A Sato; Fumiaki Jinnouchi; Shoko Ueki; Shinji Ohno; Yusuke Yanagi
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity.

Authors:  S Funke; I C Schneider; S Glaser; M D Mühlebach; T Moritz; R Cattaneo; K Cichutek; C J Buchholz
Journal:  Gene Ther       Date:  2009-02-12       Impact factor: 5.250

9.  Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus.

Authors:  Ryan S Noyce; Daniel G Bondre; Michael N Ha; Liang-Tzung Lin; Gary Sisson; Ming-Sound Tsao; Christopher D Richardson
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

10.  Optimised concentration and purification of retroviruses using membrane chromatography.

Authors:  D J McNally; D Darling; F Farzaneh; P R Levison; N K H Slater
Journal:  J Chromatogr A       Date:  2014-03-15       Impact factor: 4.759

View more
  6 in total

1.  Efficiency and Specificity of Targeted Integration Mediated by the Adeno-Associated Virus Serotype 2 Rep 78 Protein.

Authors:  Pingjuan Li; Michael P Marino; Jizhong Zou; Takele Argaw; Michael T Morreale; Brian J Iaffaldano; Jakob Reiser
Journal:  Hum Gene Ther Methods       Date:  2018-06       Impact factor: 2.396

Review 2.  Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.

Authors:  Ciprian Tomuleasa; Shigeo Fuji; Cristian Berce; Anca Onaciu; Sergiu Chira; Bobe Petrushev; Wilhelm-Thomas Micu; Vlad Moisoiu; Ciprian Osan; Catalin Constantinescu; Sergiu Pasca; Ancuta Jurj; Laura Pop; Ioana Berindan-Neagoe; Delia Dima; Shigehisa Kitano
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

Review 3.  Lentiviral Vector Bioprocessing.

Authors:  Christopher Perry; Andrea C M E Rayat
Journal:  Viruses       Date:  2021-02-09       Impact factor: 5.048

4.  In vivo targeting of lentiviral vectors pseudotyped with the Tupaia paramyxovirus H glycoprotein bearing a cell-specific ligand.

Authors:  Takele Argaw; Michael P Marino; Andrew Timmons; Lindsey Eldridge; Kazuyo Takeda; Pingjuan Li; Anna Kwilas; Wu Ou; Jakob Reiser
Journal:  Mol Ther Methods Clin Dev       Date:  2021-04-24       Impact factor: 6.698

5.  CD46 Null Packaging Cell Line Improves Measles Lentiviral Vector Production and Gene Delivery to Hematopoietic Stem and Progenitor Cells.

Authors:  Stosh Ozog; Craig X Chen; Elizabeth Simpson; Olivia Garijo; Nina D Timberlake; Petra Minder; Els Verhoeyen; Bruce E Torbett
Journal:  Mol Ther Methods Clin Dev       Date:  2018-11-24       Impact factor: 6.698

6.  Patient fibroblast circadian rhythms predict lithium sensitivity in bipolar disorder.

Authors:  Harshmeena R Sanghani; Aarti Jagannath; Thomas Humberstone; Farid Ebrahimjee; Justyn M Thomas; Grant C Churchill; Andrea Cipriani; Mary-Jane Attenburrow; Olga V Perestenko; Sally A Cowley; M Zameel Cader; Stuart N Peirson; Paul J Harrison; Russell G Foster; Guy M Goodwin; Sridhar R Vasudevan
Journal:  Mol Psychiatry       Date:  2020-05-13       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.